Brian Skorney
Stock Analyst at Baird
(3.23)
# 566
Out of 4,667 analysts
101
Total ratings
30%
Success rate
8.21%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $156.00 | +92.31% | 16 | Nov 15, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $50 | $43.69 | +14.44% | 4 | Nov 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $110.86 | +74.09% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $88.63 | +7.19% | 2 | Nov 7, 2024 | |
| ALMS Alumis | Initiates: Outperform | $25 | $9.64 | +159.34% | 1 | Oct 31, 2024 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $32 → $10 | $4.27 | +134.19% | 2 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Underperform | $215 | $287.87 | -25.31% | 4 | Sep 25, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $58 → $60 | $46.84 | +28.10% | 2 | Sep 23, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $157 → $180 | $123.29 | +46.00% | 4 | Aug 2, 2024 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $28 | $6.12 | +357.52% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $56.07 | +10.58% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $72 | $54.83 | +31.31% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $2 | $0.31 | +547.25% | 4 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.63 | +304.98% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $39.34 | +60.14% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $800 → $760 | $743.35 | +2.24% | 12 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $451.23 | -27.97% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $14 | $9.43 | +48.46% | 3 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $90 | $9.08 | +891.19% | 5 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $26.17 | -61.79% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.61 | +10,244.83% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $5.36 | +11.94% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $3.70 | +8,008.11% | 3 | May 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $194.26 | - | 2 | Nov 14, 2017 |
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $156.00
Upside: +92.31%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Outperform
Price Target: $44 → $50
Current: $43.69
Upside: +14.44%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $110.86
Upside: +74.09%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $88.63
Upside: +7.19%
Alumis
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $9.64
Upside: +159.34%
Alto Neuroscience
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $4.27
Upside: +134.19%
Amgen
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $287.87
Upside: -25.31%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $46.84
Upside: +28.10%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $123.29
Upside: +46.00%
Lexeo Therapeutics
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.12
Upside: +357.52%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $56.07
Upside: +10.58%
May 10, 2024
Initiates: Outperform
Price Target: $72
Current: $54.83
Upside: +31.31%
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $0.31
Upside: +547.25%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.63
Upside: +304.98%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $39.34
Upside: +60.14%
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $743.35
Upside: +2.24%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $451.23
Upside: -27.97%
Apr 25, 2023
Maintains: Outperform
Price Target: $18 → $14
Current: $9.43
Upside: +48.46%
May 19, 2022
Maintains: Outperform
Price Target: $130 → $90
Current: $9.08
Upside: +891.19%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $26.17
Upside: -61.79%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.61
Upside: +10,244.83%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $5.36
Upside: +11.94%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $3.70
Upside: +8,008.11%
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $194.26
Upside: -